Literature DB >> 19843100

Non-classic cystic fibrosis associated with D1152H CFTR mutation.

P-R Burgel1, I Fajac, D Hubert, D Grenet, N Stremler, M Roussey, D Siret, J Languepin, L Mely, A Fanton, A Labbé, P Domblides, P Vic, M Dagorne, M Reynaud-Gaubert, F Counil, F Varaigne, T Bienvenu, G Bellis, D Dusser.   

Abstract

BACKGROUND: Limited knowledge exists on phenotypes associated with the D1152H cystic fibrosis transmembrane conductance regulator (CFTR) mutation.
METHODS: Subjects with a D1152H allele in trans with another CFTR mutation were identified using the French Cystic Fibrosis Registry. Phenotypic characteristics were compared with those of pancreatic insufficient (PI) and pancreatic sufficient (PS) cystic fibrosis (CF) subjects in the Registry (CF cohort).
RESULTS: Forty-two subjects with D1152H alleles were identified. Features leading to diagnosis included chronic sinopulmonary disease (n = 25), congenital absence of the vas deferens (n = 11), systematic neonatal screening (n = 4), and genetic counseling (n = 2). Median age at diagnosis was 33 [interquartile range (IQR, 24-41)] years in D1152H subjects. Median sweat chloride concentrations were 43.5 (39-63) mmol/l in D1152H subjects and were markedly lower than in PI and PS CF subjects (p < 0.05). Bronchiectasis was present in 67% of D1152H subjects, but Pseudomonas aeruginosa colonization and pancreatic insufficiency were present in <30% of subjects. Estimated rates of decline in forced expiratory volume in 1 s (FEV(1)) were lower in D1152H subjects vs PI CF subjects (p < 0.05). None of the D1152H subjects identified since 1999 had died or required lung transplantation.
CONCLUSIONS: When present in trans with a CF-causing mutation, D1152H causes significant pulmonary disease, but all subjects had prolonged survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843100     DOI: 10.1111/j.1399-0004.2009.01294.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  5 in total

Review 1.  Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis.

Authors:  Benoît S Marteyn; Pierre-Régis Burgel; Laurent Meijer; Véronique Witko-Sarsat
Journal:  Front Cell Infect Microbiol       Date:  2017-06-30       Impact factor: 5.293

2.  Genetic and phenotypic traits of children and adolescents with cystic fibrosis in Southern Brazil.

Authors:  Katiana Murieli da Rosa; Eliandra da Silveira de Lima; Camila Correia Machado; Thaiane Rispoli; Victória d'Azevedo Silveira; Renata Ongaratto; Talitha Comaru; Leonardo Araújo Pinto
Journal:  J Bras Pneumol       Date:  2018 Nov-Dec       Impact factor: 2.624

3.  Image-based β-adrenergic sweat rate assay captures minimal cystic fibrosis transmembrane conductance regulator function.

Authors:  Danieli Barino Salinas; Yu-Hao Peng; Brian Horwich; Choo Phei Wee; Eric Frisbee; Jean-Michel Maarek
Journal:  Pediatr Res       Date:  2019-07-25       Impact factor: 3.953

4.  Benign and Deleterious Cystic Fibrosis Transmembrane Conductance Regulator Mutations Identified by Sequencing in Positive Cystic Fibrosis Newborn Screen Children from California.

Authors:  Danieli B Salinas; Patrick R Sosnay; Colleen Azen; Suzanne Young; Karen S Raraigh; Thomas G Keens; Martin Kharrazi
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

5.  Ivacaftor in People with Cystic Fibrosis and a 3849+10kb CT or D1152H Residual Function Mutation.

Authors:  Eitan Kerem; Malena Cohen-Cymberknoh; Reuven Tsabari; Michael Wilschanski; Joel Reiter; David Shoseyov; Alex Gileles-Hillel; Thea Pugatsch; Jane C Davies; Christopher Short; Clare Saunders; Cynthia DeSouza; James C Sullivan; Jamie R Doyle; Keval Chandarana; Nils Kinnman
Journal:  Ann Am Thorac Soc       Date:  2021-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.